Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · All participants received 18 weeks of chemotherapy with paclitaxel 80 mg/m 2 IV once weekly and non-pegylated liposomal doxorubicin 20 mg/m 2 IV once weekly. Patients with TNBC received simultaneous bevacizumab 15 mg/kg IV once every 3 weeks.
1 Αυγ 2012 · An evaluation of the combination of a standard chemotherapy (FEC100 followed by docetaxel) with panitumumab as neoadjuvant therapy of operable TNBC was recently reported with a pathological complete response rate of 65% .
15 Φεβ 2023 · Rapid clearance of ctDNA during neoadjuvant chemotherapy in early TNBC is associated with a high probability of achieving pCR [76]. In contrast, the detection of ctDNA after completion of neoadjuvant chemotherapy and surgery is associated with a higher rate of recurrence and a poorer prognosis [77].
14 Αυγ 2024 · The study aimed to assess the effectiveness and safety of dose-dense AC compared to every 3-week AC in patients with early-stage TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.
25 Ιουλ 2020 · Current guidelines recommend adjuvant chemotherapy for patients with small, lymph node–negative, triple-negative breast cancer (TNBC) measuring >5 mm (T1b disease), but clinical evidence to support this recommendation is lacking.
28 Αυγ 2023 · Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited.
29 Οκτ 2019 · NACT is associated with increased rate of pathologic complete response (pCR), which has been associated with reduced risk of death and recurrence in all subtypes, including TNBC. 3 Residual cancer burden (RCB) after NACT has also been shown to predict disease recurrence and survival across all subtypes. 8 Additionally, neoadjuvant treatment allo...
